First American Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

First American Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-14,099	Closed	-$1.31M	–	121
2017 Q3	$1.31M	Sell	14,099 -12,597	-47%	-$1.11M	0.34%	72
2017 Q2	$2.42M	Buy	26,696 +73	+0.3%	+$6.64K	0.67%	63
2017 Q1	$2.34M	Sell	26,623 -402	-1%	-$35.8K	0.71%	58
2016 Q4	$2.24M	Buy	27,025 +2,848	+12%	+$245K	0.69%	62
2016 Q3	$2.24M	Buy	+24,177	New	+$2.28M	0.7%	59

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First American Trust's BMRN Position: Q4 2017 in Review

First American Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 14,099 shares — an estimated $1.31M sold.

First American Trust first reported a position in BMRN in Q3 2016 and held it in 5 quarters. The position peaked at $2.42M in Q2 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

First American Trust reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
First American Trust sold 14,099 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $1.31M.
First American Trust first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 5 quarters.
First American Trust's BioMarin Pharmaceuticals position peaked at $2.42M in Q2 2017.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on First American Trust's 13F filing for Q4 2017, filed 11 Jan 2018.